D
Doximity, Inc.
DOCS · Healthcare
Q3 FY2026
Earning ended Dec 31, 2025Report generated Mar 10, 2026
The Physician OS Hidden Inside a Pharma Ad Business
The market is pricing Doximity as a high-quality digital media company dependent on pharma budgets — it's missing that the AI workflow layer being built right now is converting a marketing platform into clinical infrastructure, which would make the current revenue base look like a rounding error against what health systems will eventually pay for productivity tools embedded in daily care delivery.
Flowly Score
Apr 16 Close
+36%$24.25
Fair Value
$33.00
72
Strongat $24.25
Business Strength8/10
Owning the verified identity graph of virtually every practicing US physician is a cornered resource that took years to build and cannot be replicated by writing a check — the two-sided flywheel between physician engagement and pharma buyer willingness to pay is self-reinforcing at scale. The only meaningful deduction is the concentration of demand in pharma budgets, which introduces customer-side volatility into an otherwise structurally excellent business.
Financial Resilience9/10
A capital-light software platform that consistently converts nearly all reported earnings into real operating cash, runs essentially no debt, and requires almost nothing in the way of maintenance capital is about as resilient as a business gets — the Altman Z-score in the high teens is almost comically strong. The deliberate drawdown of reserves to fund buybacks is the one watch item, but it reflects conviction rather than distress.
Growth & Trajectory7/10
Revenue is reaccelerating toward double-digit growth and operating leverage is compounding earnings faster than the top line — the platform's infrastructure is largely built and incremental revenue drops through at high margins. The Q4 deceleration is a genuine caution signal: when policy events can trigger 16 of your top 20 customers to delay budget decisions simultaneously, the underlying growth rate is more volatile than the subscription label implies.
Valuation6/10at $25.49
Current price sits meaningfully below the neutral DCF estimate and well inside the optimistic scenario, which is an unusual position for a business of this quality — the multiple compression from pandemic-era highs has created a situation where you're paying a far more reasonable price for a platform that has not deteriorated. The still-elevated earnings multiple reflects the market pricing in continued mid-teens growth, which is achievable but leaves little room for another pharma budget freeze.
Risk5/10
The concentration risk is not theoretical: a single policy event — MFN drug pricing agreements signed in December — caused 16 of the top 20 pharma companies to pause budget decisions simultaneously and compress Q4 growth to near-zero, which is exactly what you'd expect from an ad-dependent business masquerading as SaaS. The Epic threat and pharma marketing regulatory exposure are credible long-duration risks sitting on top of that structural vulnerability.
The investment case here rests on a rare combination: a genuine monopoly asset (near-complete US physician coverage with verified identity) trading near or below a conservative intrinsic value estimate after substantial multiple compression. This is not a cheap business by conventional metrics, but the DCF neutral case implies upside from current levels, and the pessimistic scenario — which prices in genuine deterioration — still doesn't reflect an existential threat. What makes the quality compelling is that the moat compounds without additional capital: physician penetration is self-sustaining, and every dollar pharma spends on the platform reinforces physician engagement, which justifies more pharma spend. The free cash flow margins aren't borrowed from the future. The direction of travel matters enormously here. Three hundred thousand prescribers adopted an AI documentation tool within a single quarter of its acquisition — that's not a feature metric, that's a workflow dependency forming at speed. When physicians stop being able to do their jobs without a tool, the tool stops being optional. Management has been deliberately quiet about AI monetization timelines, but the commercialization signals point to a meaningful revenue expansion in 2027 that current numbers completely ignore. The platform is evolving from 'where doctors spend time' to 'how doctors function,' and that transition would justify a structurally higher earnings multiple than the market currently assigns. The single biggest specific risk is the one already revealed: pharma budget concentration means Doximity cannot control its own revenue trajectory when its ten largest customers simultaneously face regulatory and pricing uncertainty. The Q4 guide-down was not caused by anything Doximity did or failed to do — it was sixteen companies deciding to wait on annual budget commitments because of White House drug pricing negotiations. A business that can be slowed to near-zero growth by external events entirely outside its own operating control carries more cyclical risk than the recurring subscription label suggests, and that risk has no obvious hedge.